Rajabi, Mohammad Javad

Simorgh Research Repository

  دانشگاه علوم پزشکی و خدمات بهداشتی درمانی کرمان دارویی و علومدانشکده داروسازی   دکتری عمومی داروسازی نامه انیپا     عنوان: 6931-6931از سال  رانیدر ا ها نیازپیبنزودتقاضا  یمتیبرآورد کشش ق  توسط: محمدجواد رجبی  هنما:اساتید را زادهفاطمه دباغدکتر  محسن بارونیدکتر   اساتید مشاور: پوردکتر علی اسدی دکتر رضا گودرزی دکتر مهدی انصاری دوگاهه  6619 :نامه انیپاشماره                                       6933 زمستان Kerman University of Medical Sciences Faculty of Pharmacy  Pharm. D Thesis      Title: Estimation demand price elasticity of benzodiazepines in Iran 2007-2017    By: Mohammad Javad Rajabi    Supervisors: Dr. Fatemeh Dabaghzadeh Dr. Mohsen Barouni   Advisors: Dr. Ali Asadipour Dr. Reza Goudarzi Dr. Mehdi Ansari-Dogaheh  Winter 2021                                                     Thesis NO: 1263           خالصه یها یژگیو، به علت ها آناز ، در کنار استفاده بالینی گسترده z سریو داروهای  ها بنزودیازپین مقدمه:متشی یفراوانی قرار دارند. کشش ق  سوءمصرف، در معرض ایران اجتماعی، اقتصادی و فرهنگی کشور صشور  بهنسبت به تغییر قیمت را  دارانیخربا آن واکن  توان یماقتصاد است که  دراضا مفهومی تقمطالعه حاضر به منظور برآورد ، دارویی کشور گذاری سیاستکمی سنجید. به علت ضرور در بهبود  در ایران طراحی و اجرا شد. ها بنزودیازپینکش قیمتی تقاضا اطالعشا  ششامق قیمشت پایشه و میشزان  اسشت.  نگر گذشتهسری زمانی و  این مطالعه از نوع: هاروشو دارو وزار بهداششت  غشذا دارویشی سشازمان  یها آمارنامهاز  ها بنزودیازپینمصرف داروهای دسته بشا  هشا بنزودیشازپین استخراج شد، تابع تقاضا و میزان کش قیمتی تقاضا برای هر دارو دسته دارویشی همچنین نمودار تقاضا برای . تحلیق و بررسی شدمطالعه این در  STATA 14 داده افزار نرماستفاده از  رسم شد. 6102اکسق  افزار نرمدر  STATAدر  قبول قابقی با نتایج یداروهاو کلردیازپوکسشاید از  ونازپشام لمشخص شد داروهای آلپرازوالم تولید داخشق، ک در این مطالعه  نتایج:در ایشران  هشا  بنزودیازپینهمچنین کش قیمتی تقاضا برای دسته دارویی قانون تقاضا تبعیت نکردند.  محاسبه شد. 662/1 با انحراف معیار 206/1 برابربشرآورد  همچنین. برآورد شدکم کش در ایران جز کاالهای  ها بنزودیازپیندسته دارویی  :یریگ جهینتبر گذاری های ناکارا  نگی و سیاستاز جمله عوامق اجتماعی، فرهعوامق دیگری به غیر از قیمت شد  است. مؤثرن دسته یمیزان تقاضا برخی از داروهای ا .دارو گذاری سیاست، اقتصاد دارو، ها بنزودیازپینکش قیمتی تقاضا، : کلمات کلیدی Abstract  Introduction: Benzodiazepines and z-series drugs, in addition to their widespread clinical use, are exposed to widespread abuse due to the social, economic and cultural characteristics of Iran. Price elasticity of demand is a concept in the economy that can be used to quantify the reaction of buyers to price changes. Due to the need to improve the country's pharmaceutical policy, the present study was designed and conducted to estimate the price elasticity of demand for benzodiazepines in Iran. Method: This study was a time-series and retrospective. Data including price and amount of demand of benzodiazepines were extracted from the statistics from Food and Drug Administration of the Ministry of Health of Iran. The demand function and the price elasticity of demand for each drug analyzed and estimated by using STATA 14 econometric software. Also, the demand curve for drugs with acceptable results in STATA was drawn in Excel 2016 software. Results: we found the alprazolam that produce domestically; clonazepam and chlordiazepoxide did not follow the law of demand in Iran. Also, the price elasticity of demand for benzodiazepines in Iran was calculated to be 0.412 with a standard deviation of 0.227. Conclusion: Benzodiazepines in Iran was considered an inelastic and essential good. It was also estimated that factors other than price affect the demand for some drugs in this class. Keywords: Price Demand of Elasticity, Benzodiazepines, Pharmacoeconomics, Drug Policy      فهرست مطالب صفحه           عنوان  I ............................................................................................................. خالصهAbstract ......................................................................................................... II  III .................................................................................................. فهرست مطالب V ................................................................................................ هافهرست جدول VI ................................................................................................. هافهرست شکق VII ............................................................................................. فهرست نمودارها VIII ....................................................................................... هانوشتهفهرست کوتاه مقدمه فصل اول: 6 .................................................................................. هدف و اهمیت مطالعه -0-0 3 ................................................... مفهوم قانون تقاضا، کش و کش قیمتی تقاضا -0-6 z ............................................... 2معرفی دسته دارویی بنزودیازپین و داروهای سری  -0-3 01 ............................................................................. بررسی چند مطالعه مرتبط -0-2 ها ها و دستگاه مواد و روش فصل دوم: 03 ................................................................................................ روش کار -6-0 02 ...................................................................................... مالحظا اخالقى -6-6 02 ....................................................................................... هاآوری داده جمع -6-3 02 ...................................................... ها افزارهای مورد استفاده برای تحلیق داده نرم -6-2 05 ........................................................... ها وتحلیق داده معیارهای ارزیابی و تجزیه -6-5  نتایج :فصل سوم 61 .....................ها قدار کش هر دارو از دسته بنزودیازپیننتایج حاصق از تابع تقاضا و م -3-0 32 .............................................. نتایج کش قیمتی تقاضا دسته دارویی بنزودیازپینی -3-6 گیری بحث و نتیجه فصل چهارم: 33 ...................................................................................................... بحث -2-0 23 ............................................................................................... گیری نتیجه -2-6 منابع 25 .............................................................................................................. منابع     منابع[1] Lynch T, Ryan C, Hughes CM, et al. Brief interventions targeting long-term benzodiazepine and Z-drug use in primary care: a systematic review and meta-analysis. Addiction 2020; 115:1618–1639.  [2] Cornett EM, Novitch MB, Brunk AJ, et al. New benzodiazepines for sedation. Best Pract Res Clin Anaesthesiol 2018; 32:149–164.  [3] Haut SR, Seinfeld S, and Pellock J. Benzodiazepine use in seizure emergencies: A systematic review. Epilepsy Behav 2016; 63:109–117.  [4] Thibaut F. Anxiety disorders: A review of current literature. Dialogues Clin Neurosci 2017; 19:87–88.  [5] Riemann D, Baglioni C, Bassetti C, et al. European guideline for the diagnosis and treatment of insomnia. J Sleep Res 2017; 26:675–700.  [6] Richards BL, Whittle SL, and Buchbinder R. Muscle relaxants for pain management in rheumatoid arthritis. Cochrane Database Syst Rev 2012.  [7] de la Iglesia-Larrad JI, Barral C, Casado-Espada NM, et al. Benzodiazepine abuse, misuse, dependence, and withdrawal among schizophrenic patients: A review of the literature. Psychiatry Res 2020; 284.  [8] Noorbala AA, Saljoughian A, Bagheri Yazdi SA, et al. Evaluation of drug and alcohol abuse in people aged 15 years and older in Iran. Iran J Public Health 2020; 49:1940–1946.  [9] Intermediate Microeconomics with Applications. In: Intermediate Microeconomics with Applications. 1980.  [10] Gatwood J, Gibson TB, Gibson TB, et al. Price elasticity and medication use: Cost sharing across multiple clinical conditions. J Manag Care Spec Pharm 2014; 20:1102–1107.  [11] Petry NM and Bickel WK. Polydrug abuse in heroin addicts: A behavioral economic analysis. Addiction 1998; 93:321–335.  [12] Petry NM. A behavioral economic analysis of polydrug abuse in alcoholics: Asymmetrical substitution of alcohol and cocaine. Drug Alcohol Depend 2001; 62:31–39.  [13] Meyerhoefer CD and Zuvekas SH. New estimates of the demand for physical and mental health treatment. Health Econ 2010; 19:297–315.    [14] McClellan C, Fingar KR, Ali MM, et al. Price elasticity of demand for buprenorphine/naloxone prescriptions. J Subst Abuse Treat 2019; 106:4–11.  [15] N. Gregory Mankiw. Principles of Economics. In: Cengage Le. Boston; 2020; 63–68.  [16] Ahsan S and Samuelson L. Microeconomic Theory. Vol. 21, The Canadian Journal of Economics. 1988; 436.  [17] Sweeny K. The impact of copayments and safety nets on PBS expenditure. Aust Heal Rev 2009; 33:215–230.  [18] Jembrek M and Vlainic J. GABA Receptors: Pharmacological Potential and Pitfalls. Curr Pharm Des 2015; 21:4943–4959.  [19] Wisden W, Yu X, and Franks NP. GABA Receptors and the Pharmacology of Sleep. Handb Exp Pharmacol 2019; 253:279–304.  [20] Nelson AC, Kehoe J, Sankoff J, et al. Benzodiazepines vs barbiturates for alcohol withdrawal: Analysis of 3 different treatment protocols. Am J Emerg Med 2019; 37:733–736.  [21] Machado C, Estévez M, and Rodriguez-Rojas R. Zolpidem efficacy and safety in disorders of consciousness. Brain Inj 2018; 32:530–531.  [22] Jaffé G. Barbiturates for Insomnia. Lancet 1964; 283:833–834.  [23] Wick JY. The history of benzodiazepines. Consult Pharm 2013; 28:538–548.  [24] https://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019908_S000_AmbienTOC.cfm.  [25] Chiaro G, Castelnovo A, Bianco G, et al. Severe Chronic Abuse of Zolpidem in Refractory Insomnia. J Clin Sleep Med 2018; 14:1257–1259.  [26] Starcevic V, Berle D, Do Rosário MC, et al. Use of benzodiazepines in obsessive-compulsive disorder. Int Clin Psychopharmacol 2016; 31:27–33.  [27] Kriegel DL and Azrak A. Benzodiazepines for Panic Disorder in Adults. Am Fam Physician 2020; 101.  [28] Guina J, Rossetter SR, Derhodes BJ, et al. Winner of resident paper award 2014: Benzodiazepines for PTSD: A systematic review and meta-analysis. J Psychiatr Pract 2015; 21:281–303.    [29] Sivaramakrishnan G and Sridharan K. Nitrous oxide and midazolam sedation: A systematic review and meta-Analysis. Anesth Prog 2017; 64:59–65.  [30] Kosten TR and Baxter LE. Review article: Effective management of opioid withdrawal symptoms: A gateway to opioid dependence treatment. Am J Addict 2019; 28:55–62.  [31] Schmidt KJ, Doshi MR, Holzhausen JM, et al. Treatment of Severe Alcohol Withdrawal. Ann Pharmacother 2016; 50:389–401.  [32] Bhattacharyya N, Gubbels SP, Schwartz SR, et al. Clinical Practice Guideline: Benign Paroxysmal Positional Vertigo (Update). Otolaryngol - Head Neck Surg (United States) 2017; 156:S1–S47.  [33] Moss MJ and Hendrickson RG. Serotonin Toxicity: Associated Agents and Clinical Characteristics. J Clin Psychopharmacol 2019; 39:628–633.  [34] Schönfeldt-Lecuona C, Kuhlwilm L, Cronemeyer M, et al. Treatment of the Neuroleptic Malignant Syndrome in International Therapy Guidelines: A Comparative Analysis. Pharmacopsychiatry 2020; 53:51–59.  [35] Adel N. Overview of chemotherapy-induced nausea and vomiting and evidence-based therapies. Am J Manag Care 2017; 23:S259–S265.  [36] Olfson M, King M, and Schoenbaum M. Benzodiazepine use in the United States. JAMA Psychiatry 2015; 72:136–142.  [37] RAJAH A. The use of diazepam in chloroquine poisoning. Anaesthesia 1990; 45:955–957.  [38] Ellison SF, Cockburn I, Griliches Z, et al. Characteristics of Demand for Pharmaceutical Products: An Examination of Four Cephalosporins. RAND J Econ 1997; 28:426.  [39] Rizzo JA. Advertising and competition in the ethical pharmaceutical industry: The case of antihypertensive drugs. J Law Econ 1999; 42:89–116.  [40] Douglas PH. The Cobb-Douglas Production Function Once Again: Its History, Its Testing, and Some New Empirical Values. J Polit Econ 1976; 84:903–915.  [41] Bee Wah Y and Mohd Razali N. Power comparisons of Shapiro-Wilk, Kolmogorov-Smirnov, Lilliefors and Anderson-Darling tests. J Stat Model Anal 2011; 2:21–33.  [42] Katzung BG. Basic & Clinical Pharmacology, 14th Ed. Basic and Clinical Pharmacology. 2018.   [43] Chisholm D, Healey A, and Knapp M. QALYs and mental health care. Soc Psychiatry Psychiatr Epidemiol 1997; 32:68–75.  [44] Zarafshan H, Mohammadi MR, and Salmanian M. Prevalence of anxiety disorders among children and adolescents in Iran: A systematic review. Iran J Psychiatry 2015; 10:1–7.  [45] Torbat AE and Torbat AE. The Economic Sanctions Against Iran. Polit Oil Nucl Technol Iran 2020; 201–224.  [46] Hemmati A, Niakan L, and Varahrami V. The external determinants of inflation: The case of Iran. Iran Econ Rev 2018; 22:741–752.  [47] Ghorbani Dastgerdi H, Yusof ZB, and Shahbaz M. Nexus between economic sanctions and inflation: a case study in Iran. Appl Econ 2018; 50:5316–5334.  [48] Murphy JM, Olivier DC, Monson RR, et al. Depression and Anxiety in Relation to Social Status: A Prospective Epidemiologic Study. Arch Gen Psychiatry 1991; 48:223–229.  [49] Salari N, Hosseinian-Far A, Jalali R, et al. Prevalence of stress, anxiety, depression among the general population during the COVID-19 pandemic: A systematic review and meta-analysis. Global Health 2020; 16.  [50] Mohamadloo A, Zarein-dolab S, Ramezankhani A, et al. The Main Factors of Induced Demand for Medicine Prescription  : A Qualitative Study. Iran J Pharm Res 2019; 18:479–487.  [51] Mumford GK, Evans SM, Fleishaker JC, et al. Alprazolam absorption kinetics affects abuse liability. Clin Pharmacol Ther 1995; 57:356–365.  [52] Dutt M, Dharavath R, Kaur T, et al. Co-abuse of alprazolam augments the hepato-renal toxic effects of methylphenidate. Indian J Pharmacol 2020; 52:216–221.  [53] McCabe SE, Knight JR, Teter CJ, et al. Non-medical use of prescription stimulants among US college students: Prevalence and correlates from a national survey. Addiction 2005; 100:96–106.  [54] Jones JD, Mogali S, and Comer SD. Polydrug abuse: A review of opioid and benzodiazepine combination use. Drug Alcohol Depend 2012; 125:8–18.  [55] Masuade Babakhanian, Maliheh Sadeghi , Nader Mansoori , Zahra Alam Mehrjerdi MT. Nonmedical Abuse of Benzodiazepines in Opiate-Dependent Patients in Tehran, Iran. Iran J Psychiatry Behav Sci 2012; 6.    [56] Høiseth G, Middelkoop G, Mørland J, et al. Has previous abuse of flunitrazepam been replaced by clonazepam? Eur Addict Res 2015; 21:217–221.  [57] A Rahbar, M Barouni, MA Bahrami * ASM. Estimation of Drug Demand Function in Iranian Urban Population through Household Budget, 1990-2011. J Toloo-e-behdasht 2013; 12:44–58.  [58] Van Vliet RCJA. Effects of price and deductibles on medical care demand, estimated from survey data. Appl Econ 2001; 33:1515–1524.  [59] Siminski P. The price elasticity of demand for pharmaceuticals amongst highincome older Australians: A natural experiment. Appl Econ 2011; 43:4835–4846.  [60] McManus P, Donnelly N, Henry D, et al. Prescription drug utilization following patient co-payment changes in Australia. Pharmacoepidemiol Drug Saf 1996; 5:385–392.       

برآورد کشش قیمتی تقاضا بنزودیازپین‌ها در ایران از سال ۱۳۹۶-۱۳۸۶

http://eprints.kmu.ac.ir/35883/1/8290.pdf

برآورد کشش قیمتی تقاضا بنزودیازپین‌ها در ایران از سال ۱۳۹۶-۱۳۸۶

Abstract

Similar works

Full text

Available Versions

Simorgh Research Repository